Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
DRUG

Metformin Versus a combination of Metformin and Thymoquinone (TQ)

Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.

Trial Locations (1)

41311

Saudi German Hospital, Al Madīnah

All Listed Sponsors
lead

Saudi German Hospital - Madinah

OTHER

NCT04852510 - Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin | Biotech Hunter | Biotech Hunter